Thalassemia Market Poised to Hit USD 4.2 billion by 2031, Driven by a 5.0% CAGR: Insights from Allied Market Research

According to the report published by Allied Market Research, the global Thalassemia Market garnered USD 2.5 billion in 2021 and is estimated to generate USD 4.2 billion by 2031, manifesting a CAGR of 5.0% from 2022 to 2031. The report provides an extensive analysis of changing market dynamics, major segments, value chain, competitive scenario, and regional landscape. This research offers a valuable guidance to leading players, investors, shareholders, and startups in devising strategies for the sustainable growth and gaining competitive edge in the market.

𝐖𝐡𝐚𝐭 𝐚𝐫𝐞 𝐭𝐡𝐞 𝐃𝐫𝐢𝐯𝐢𝐧𝐠 𝐅𝐚𝐜𝐭𝐨𝐫𝐬 𝐎𝐟 𝐓𝐡𝐚𝐥𝐚𝐬𝐬𝐞𝐦𝐢𝐚 𝐌𝐚𝐫𝐤𝐞𝐭?

Growth & innovations in the pharmaceutical industry for the manufacturing of thalassemia drugs owing to massive pool of health conscious consumers serve as potential opportunities for the expansion of the global thalassemia market. Based on region, North America held the largest share in 2021, contributing to nearly half of the global thalassemia market share.

𝐆𝐞𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐑𝐞𝐩𝐨𝐫𝐭 𝐰𝐢𝐭𝐡 𝐆𝐫𝐚𝐩𝐡𝐬 𝐚𝐧𝐝 𝐅𝐢𝐠𝐮𝐫𝐞𝐬 𝐇𝐞𝐫𝐞: https://www.alliedmarketresearch.com/request-sample/15812

Covid-19 Scenario:

• The outbreak of COVID-19 had disrupted workflows in the health care sector around the world. The thalassemia market experienced a decline in 2021, due to global economic recession led by COVID-19.
• In addition, the COVID-19 outbreak disrupted the supply chain of thalassemia drugs across various end-user industries like hospitals and pharmacies.
• However, the market is anticipated to witness recovery in 2021, and show stable growth in the coming future. This is attributed to the increase in adoption of various screening techniques during pregnancy for genetic abnormalities and proper counselling regarding thalassemia.

𝐓𝐨𝐩 𝐓𝐡𝐚𝐥𝐚𝐬𝐬𝐞𝐦𝐢𝐚 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬

• FRESENIUS SE & Co
• KGaA (Fresenius Kabi)
• Apotex Inc
• Novartis AG
• Pfizer Inc.
• Sun Pharmaceutical Industries Limited
• Alvogen Inc
• Bluebirdbio
• Bristol Myers Squibb Co.
• Chiesi Farmaceutici S.p.A
• Cipla Ltd.

The report provides a detailed analysis of these key players of the global thalassemia market. These players have adopted different strategies such as new product launches, collaborations, expansion, joint ventures, agreements, and others to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.

𝐓𝐡𝐚𝐥𝐚𝐬𝐬𝐞𝐦𝐢𝐚 𝐌𝐚𝐫𝐤𝐞𝐭 𝐬𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 𝐜𝐚𝐧 𝐛𝐞 𝐝𝐨𝐧𝐞 𝐛𝐚𝐬𝐞𝐝 𝐨𝐧 𝐬𝐞𝐯𝐞𝐫𝐚𝐥 𝐟𝐚𝐜𝐭𝐨𝐫𝐬, 𝐢𝐧𝐜𝐥𝐮𝐝𝐢𝐧𝐠:

The research provides detailed segmentation of the global thalassemia market based on treatment, type, distribution channel, and region. The report discusses segments and their sub-segments in detail with the help of tables and figures. Market players and investors can strategize according to the highest revenue-generating and fastest-growing segments mentioned in the report.

Based on treatment, the iron chelation therapy segment held the highest share in 2021, accounting for more than half of the global thalassemia market, and is expected to continue its leadership status during the forecast period. However, the others segment is expected to register the highest CAGR of 5.5% from 2022 to 2031.

Based on type, the alpha thalassemia segment accounted for the highest share in 2021, contributing to  more than three-fourths of the global thalassemia market, and is expected to maintain its lead in terms of revenue during the forecast period. This segment is expected to manifest the highest CAGR of 5.4% from 2022 to 2031.

Based on distribution channel, the drug stores and retail pharmacies segment accounted for the highest share in 2021, holding more than half of the global thalassemia market, and is expected to continue its leadership status during the forecast period. However, the online providers segment is estimated to grow at the highest CAGR of 6.7% during the forecast period.

Based on region, North America held the largest share in 2021, contributing to nearly half of the global thalassemia market share, and is projected to maintain its dominant share in terms of revenue in 2031. In addition, the Asia-Pacific region is expected to manifest the fastest CAGR of 6.8% during the forecast period.

𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐭𝐡𝐞 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.alliedmarketresearch.com/purchase-enquiry/15812

Our Market Research Solution Provides You Answer to Below Mentioned Question:

• Which are the driving factors responsible for the growth of market?
• Which are the roadblock factors of this market?
• What are the new opportunities, by which market will grow in coming years?
• What are the trends of this market?
• Which are main factors responsible for new product launch?
• How big is the global & regional market in terms of revenue, sales and production?
• How far will the market grow in forecast period in terms of revenue, sales and production?
• Which region is dominating the global market and what are the market shares of each region in the overall market in 2022?
• How will each segment grow over the forecast period and how much revenue will these segments account for in 2030?
• Which region has more opportunities?

By Region Outlook 

• North America
  (U.S., Canada, Mexico)
• Europe
  (Germany, France, UK, Italy, Spain, Rest of Europe)
• Asia-Pacific
  (Japan, China, India, Rest of Asia-Pacific)
•  LAMEA
  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)

Contact Details:

David Correa
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
help@alliedmarketresearch.com

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.